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Summary
In this exciting era, we are coming closer and closer to bringing an anti-inflammatory therapy to 
the clinic for the purpose of seizure prevention, modification, and/or suppression. At present, it is 
unclear what this approach might entail, and what form it will take. Irrespective of the therapy that 
ultimately reaches the clinic, there will be some commonalities with regard to clinical trials. A 
number of animal models have now been used to identify inflammation as a major underlying 
mechanism of both chronic seizures and the epileptogenic process. These models have 
demonstrated that specific anti-inflammatory treatments can be effective at both suppressing 
chronic seizures and interfering with the process of epileptogenesis. Some of these have already 
been evaluated in early phase clinical trials. It can be expected that there will soon be more clinical 
trials of both “conventional, broad spectrum” anti-inflammatory agents and novel new approaches 
to utilizing specific anti-inflammatory therapies with drugs or other therapeutic interventions. A 
summary of some of those approaches appears below, as well as a discussion of the issues facing 
clinical trials in this new domain.
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Anti-inflammatory treatments may add to the therapeutic armamentarium and help to 
suppress seizures in epilepsies that are refractory to conventional antiepileptic drugs 
(AEDs). Although trial methodology for classical AEDs is well established, evaluation of 
anti-inflammatory treatments for epilepsy has to respect a variety of additional factors, and 
trial design may become more complex for reasons that will become clear in the sections 
below. There is expectation and hope that these treatments may even display a true 
antiepileptogenic effect; a trial to prevent poststroke epilepsy will be discussed in this article. 
The anti-inflammatory and antiepileptogenic potential of other compounds already in use, 
like anakinra for rheumatoid arthritis and autoinflammatory diseases and fingolimod for 
multiple sclerosis, is presented here. Steroids are increasingly in use for the treatment of 
some epileptic syndromes where an inflammatory cause is suspected. This article presents 
the rationale behind the administration of these well-known large-spectrum 
immunosuppressant drugs and weighs their expected benefits against their imminent harms. 
Cannabinoids modulate the nervous and immune systems by various pathways that will be 
discussed together with their potential as antiseizure and antiepileptogenic drugs. 
Nonpharmaceutical therapies for refractory epilepsy such as the ketogenic diet or vagus 
nerve stimulation also influence the immune system and exert anti-inflammatory effects, 
which will be addressed in the following chapter.
Clinical Trials of Anti-Inflammatory Agents
(Jacqueline A. French)
Inflammation may be critical to both development and perpetuation of an epileptic focus, 
and the underlying mechanisms for each may differ.1 Thus an anti-inflammatory drug may 
be effective as an antiepileptogenic agent, an anti-ictal agent that suppresses seizures in the 
chronic state, or both. Moreover, the impact may simply be to suppress seizures, or may be 
disease-modifying. Clinical trial design will differ substantially depending on the purpose of 
the trial. Anti-ictal studies are those studies that are performed to determine if the drug can 
reduce or eliminate ongoing seizures in treatment-resistant patients. These would be similar 
to studies performed for anti-ictal drugs with other mechanisms, but there may be some 
special considerations for a drug with anti-inflammatory properties. One issue would be 
patient selection. To date, preclinical studies have suggested that some degree of 
inflammation may be present in all patients with chronic epilepsy. However, it is possible 
that specific etiologies, such as mesial temporal sclerosis (MTS), cortical dysplasia, and 
tuberous sclerosis have a greater component of inflammation driving ictogenesis.2 If this is 
correct, it would be prudent to find patients with these specific etiologies. In addition,, 
inflammation may be more active at some points in the course of epilepsy than in others. It 
may not be simple to identify patients who have active inflammation contributing to 
ictogenesis, and limiting patients to those with specific etiologies may lead to poor 
recruitment. In future studies, it will be critical to enrich the trial population with responders, 
to increase effect size. Identification of imaging and/or blood biomarkers will be critical to 
this effort. Alternative solutions may be “enriched studies” in which patients are initially 
treated in an open-label fashion, and only responders undergo a randomized clinical trial 
(RCT), or adaptive trials, in which nonresponders are discontinued early.
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Because anti-inflammatory therapies might work in a different way than standard AEDs, the 
timing of onset and offset of the effect may also be different. Specifically, an anti-
inflammatory therapy may take time to exert its effect, and may continue to have an effect 
after it is withdrawn. An example is VX-765, an anti-inflammatory drug that specifically 
inhibits interleukin-converting enzyme (ICE), thereby reducing interleukin (IL)-1β 
biosynthesis and high mobility group box 1 (HMGB1) release, two molecules implicated in 
seizure mechanisms in experimental models.1 VX-765 is the only known anti-inflammatory 
agent that has been used for controlled efficacy trials in chronic focal epilepsy, although 
these trials were only preliminary.3 Animal studies showed a delayed start of the antiseizure 
effect of the anti-inflammatory molecule.4 This was ignored when designing the first study, 
which was very short, possibly leading to a failed trial. Only a post hoc analysis showed a 
probable effect, starting 1–2 weeks after drug initiation. There was also a suggestion of a 
delayed return to baseline seizure frequency after the drug was withdrawn. Unfortunately, 
the second study of this drug was terminated after only 10 subjects/arm were enrolled, due 
to change of priorities on the part of the pharmaceutical company that was developing the 
molecule. Nonetheless, some very important lessons were learned that can and should be 
used to inform future trials of anti-inflammatory interventions.
No trials have been done in epilepsy that specifically contain an endpoint to demonstrate 
disease modification. Disease modification trials have been planned and attempted in other 
chronic central nervous system (CNS) diseases such as Alzheimer’s and Parkinson’s 
disease.5,6 Trial design options include those that capitalize on delayed start, continued 
benefit after treatment discontinuation, and active comparison to a non-disease-modifying 
drug with comparison of slope of improvement over time. These trials may not be easy to 
perform, and there will need to be some understanding of time to effect and other drug 
characteristics, to increase the odds of success. Again, biomarkers would be helpful to 
determine improvement along the way, particularly if there might be substantial delay to 
effect.
Future directions
Trials to demonstrate antiepileptogenic effects would be the most difficult, and would 
require careful preclinical studies demonstrating a strong effect of the compound in animal 
models at relevant doses, duplicated in at least two studies or through a multicenter 
collaboration. Because most epilepsy risk factors (such as traumatic brain injury and stroke) 
cause epilepsy in only a subset of affected individuals (typically 10–25%), and epilepsy does 
not usually develop immediately, trials would need to be long, and would need to recruit a 
large number of patients. The burden of the therapy should match the potential expected risk 
reduction, and the trial would have to be planned in such a way that the population is 
recruitable. Many previous antiepileptogenesis trials have failed due to poor recruitment, or 
other design flaws.7 Availability of biomarkers could substantially increase the likelihood of 
success by either enriching recruitment for patients who will develop epilepsy, or providing 
an early indicator of benefit.
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A Proposal for an Anti-epileptogenesis Trial in Post-stroke Epilepsy
(Matthias Koepp)
Stroke is the third leading cause of death and a major cause of disability in Europe; it affects 
one in six adults with an estimated 3–6 million stroke cases annually.8 Individuals who have 
had a stroke have an increased risk of epilepsy (~10%),9 with most epilepsy cases occurring 
within 24 months after stroke. When unprovoked seizures occur, they further impair an 
already compromised quality of life, worsen the degree of cognitive disability, and are 
associated with an increased risk of subsequent dementia.10 There are no treatments to 
prevent the development of these disabling comorbidities11 and there are only few effective 
pharmacologic interventions that facilitate poststroke recovery.12
Although progress has been made in understanding the cellular and molecular mechanisms 
of ischemic tissue damage, neuroprotective and regenerative treatments that could improve 
outcome in patients recovering from stroke are lacking. Stroke induces a complex cascade of 
different inflammatory mediators and cytokines, and aging, a risk factor for stroke, further 
exacerbates neuroinflammatory responses. There is increasing evidence that inflammatory 
changes in the brain after stroke also promote the development of epilepsy, that is, 
epileptogenesis, among many other changes through processes triggered by the pro-
inflammatory cytokine interleukin (IL)-1β and inhibited by the endogenous IL-1 receptor 
antagonist (IL-1ra).1,13,14 Because epileptogenesis is variable and only a minority of patients 
develop epilepsy following stroke,15 clinical trials of potentially disease-modifying 
treatments would benefit greatly from the ability to identify reliably those individuals who 
are most likely to develop epilepsy after stroke.
Rationale for repurposing an anti-inflammatory compound
Major advances have been made in understanding basic mechanisms of epileptogenesis and 
epilepsy in a variety of animal models. Among etiologies of epilepsy, which are readily 
detectable and could permit early interventions, stroke stands out prominently, particularly 
because patients at-risk and associated epileptogenic mechanisms can be identified within a 
reasonable time from the insult. One mechanism that has emerged as having primary 
importance for recovery from stroke and epileptogenesis, is brain inflammation. The 
available preclinical data support the hypothesis that brain inflammation can play a crucial 
role not only in promoting epileptogenesis after stroke, but also in sustaining recurrence of 
seizures once an epileptic condition has become established.16
There is evidence indicating that centrally active anti-inflammatory agents can exert 
neuroprotective effects in animal models of seizure-related cell damage: administration of 
the human recombinant IL-1ra (anakinra) for 7 days after pilocarpine- or electrically 
induced status epilepticus (ElectrSE) yielded therapeutic drug levels in brain, and decreased 
both IL-1β expression in astrocytes and cell loss in rat forebrain.17 Anakinra given in 
combination with VX-765, a specific inhibitor of the biosynthetic enzyme of IL-1β, afforded 
significant neuroprotection in the ElectrSE rat model when given as an intravenous bolus (33 
mg/kg, 10 mg/200 μL) followed by sustained subcutaneous infusion with osmotic 
minipumps (24 mg/day; 80 mg/kg/day) for 1 week starting 3 h after the onset of status 
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epilepticus. Anakinra treatment was based on previous evidence of neuroprotection in rat 
and human stroke.18 Immunohistochemical analysis of brain sections at the end of treatment 
showed reduction in IL-1β expression in glial cells concomitant with neuroprotection in 
forebrain areas. However, onset of epilepsy and frequency and duration of seizures assessed 
3 months after ElectrSE were not significantly modified. In subsequent studies, however, the 
combination of anakinra with a cyclooxygenase-2 (COX-2) inhibitor, or with BoxA, a 
peptide blocking the effects of the inflammatory molecule HMGB1, administered at the time 
of status epilepticus induction, was able to significantly decrease spontaneous seizures in 
rats.
Therefore, there is a clear rationale for conducting a proof-of-concept study to test the ability 
of IL-1 antagonists to inhibit brain inflammation in stroke patients. Demonstration of a 
central anti-inflammatory action of IL-1 antagonists in the relevant human population is the 
prerequisite for the design and execution of a randomized controlled trial to determine 
whether these agents are also effective in achieving inhibition of epileptogenesis, and 
functional recovery after insult.
Objectives for antiepileptogenesis trial
The development of new, potentially antiepileptogenic therapies has been stagnating, partly 
due to lack of clinically validated biomarkers to reliably predict who is most likely to 
develop epilepsy in a short time frame. In fact, currently available tools (e.g., routine 
magnetic resonance imaging [MRI] and electroencephalography [EEG]), are not accurate 
predictors for the risk of future seizures, or for the need to start antiepileptic drug treatment 
after a first unprovoked seizure.
Thus specific objectives for an antiepileptogenesis trial are the following:
1. To evaluate the efficacy of a novel therapeutic strategy in patients following 
stroke who are at highest risk of developing epilepsy.
As a first step, it is important to measure the development of a hyperexcitable 
state following an initial epileptogenic lesion, which underpins the process 
leading to the occurrence of late unprovoked seizures. Because it is 
inconceivable to test putative antiepileptogenic drugs over long periods in 
populations with a very low (<10% over 2 years) risk of a seizure, the challenge 
is to identify an enriched population of patients with the highest risk of 
developing epilepsy after stroke. Stroke patients who develop one or more acute 
symptomatic seizures represent a potentially adequate population for such a trial, 
as their risk of subsequently developing unprovoked seizures, that is, epilepsy, is 
about 30% over 2 years.19
2. To quantitate the response to anti-inflammatory treatment using imaging, 
electrophysiologic, and circulating biomarkers.
The “conditio-sine-qua-non” of an antiepileptogenic treatment targeting 
poststroke brain inflammation is to demonstrate its capacity to reduce 
inflammation in the CNS. This may be possible by measuring inflammatory 
serum biomarkers mirroring brain inflammation, but more specifically by 
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imaging brain inflammatory changes directly using positron emission 
tomography (PET) ligands for translocator protein 18 kDa (TSPO), which 
measure in vivo microglial activation.20 TSPO is normally only lightly expressed 
in the brain, but it is drastically upregulated in response to neuroinflammatory 
stimuli. This upregulation correlates with microglial activation or infiltration of 
macrophages following stroke.21
3. To determine the capacity of biomarkers to predict the development of poststroke 
epilepsy.
An alternative to evaluating the efficacy of the intervention in preventing epilepsy is to 
assess the effect of the intervention on appropriate surrogate biomarkers of epileptogenesis 
with sufficient sensitivity and specificity. Even within the high-risk group, the risk of 
recurrent seizures will remain below 20% at 1 year. Identification of reliable biomarkers for 
epileptogenesis would facilitate and shorten targeted trials of novel antiepileptogenic 
therapies.
Future directions
The quest for appropriate surrogate biomarkers with sufficient sensitivity and specificity is 
essential for evaluating novel interventions during short-term trials, as well as for identifying 
populations at higher risk of developing epilepsy than those who can be currently selected. 
In patients with stroke, the risk of recurrent seizure remains below 10% at 2 years. Thus we 
propose to focus on an enriched population of patient with stroke and an acute symptomatic 
seizure, that is, those with the highest risk (~30%) of developing epilepsy.
Fingolimod (FTY720), Is It a Potential Antiepileptic Drug?
(Yvonne Naegelin)
FTY720 has been developed after being isolated from the fungus Isaria sinclairii. The 
synthetic compound fingolimod (Gilenya, 2-amino-2-(2-(4-octylpheyl)ethyl)propane-1,3-
diol, C19H33NO2) acts mainly over sequestration of circulating lymphocytes to the lymph 
nodes without major alterations of their immune functions. It was meant to prevent allograft 
rejection without inducing a severe immunosuppression but did not show enough 
immunosuppressive effect in the context of tissue transplantation.22 It did so, in the context 
of multiple sclerosis (MS), where it was the first oral drug being approved for relapsing 
remitting forms, reducing the annual relapse rate by roughly 50%.23 Acceleration of homing 
and blocking egress from lymph nodes (over sphingosine 1-phosphate (S1P1) receptor 
downregulation) is thought to be the main mode of action for its efficacy in MS.24
It is well established that inflammation can be a consequence as well as a cause of 
epilepsy.25 In contrast to the pathogenesis of MS, where there is a marked activation of the 
adaptive immune system with infiltrating B and T lymphocytes,26 brain inflammation in 
epilepsy is dominated by innate immunity cells including activated microglia, astrocytes, as 
well as granulocytes and monocytes/macrophages.27 There seems to be a link between the 
innate and adaptive immuneresponse,28,29 possibly explaining why there is some evidence 
of a scarce presence of adaptive immune cells such as T or B cells in nonautoimmune forms 
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of epilepsy such as TLE.27,28,30 In general, the involvement of the adaptive immunity 
appears to be much more related to the autoimmune forms of epilepsy.31
Nevertheless, the two entities might share some common pathways and therefore some 
treatment approaches.
FTY720 is a potent nonselective agonist at S1P1 and S1P3–5 receptors.32 FTY720 has a 
half-life of 6 days and reaches steady-state blood concentrations after 1–2 months of daily 
dosing. It reduces lymphocytes (homing) within hours after first dose administration, an 
effect being fully reversible within 6–8 weeks after stopping treatment.33 Its second most 
relevant and temporary side effect for clinical applications (negative chronotropy) is caused 
by targeting S1P1 and S1P3 receptors on atrial myocytes. FTY720 crosses the blood-brain 
barrier (BBB)34 to bind S1P receptors located on neural cells in the CNS (S1P1, -3, -5). The 
S1P2 receptor is located on neural cells as well but not targeted by FTY720. The S1P4 
receptor is located only on lymphocytes, but the major effect on lymphocytes is induced by 
targeting S1P1 receptors on those cells. FTY720 is phosphorylated by sphingosine kinases 
to FTY720-P.35 This probably is taking place within the CNS: after oral administration of 
FTY720, the brain concentrations of FTY720 are 10–27-fold higher than peripheral 
concentrations.34 Within the brain, FTY720 and FTY720-P reach nearly the same 
concentrations.34
S1P receptors are also enriched on astrocytes, and these cells are key players in the 
generation and perpetuation of brain inflammation both in MS and epilepsy as well as in the 
formation and preservation of the BBB.36 FTY720-P mediates anti-inflammatory effects on 
astrocytes as well as extracellular-signal regulated kinase (ERK) phosphorylation by 
activation of S1P1.37 The ERK cascade regulates many distinct processes such as 
proliferation, differentiation, survival, as well as apoptosis of cells. Some data do link ERK 
activation to epilepsy, but its involvement is still not fully understood. In vitro experiments 
show a beneficial effect by FTY720-P and FTY720 on endothelial cells, and S1P 
modulation seems to reduce transmigration of peripheral blood mononuclear cells through 
the BBB.38
In summary, there are various direct effects of FTY720 on the CNS resident cells that go far 
beyond the homing of peripheral lymphocytes, and most of them are thought to be receptor 
mediated.39 These effects may contribute to the therapeutic actions of this drug.
Apart from those receptor-mediated effects, FTY720-P directly binds to histone deacetylase 
(HDAC), thereby possibly having a direct effect on epigenetic gene regulation.40 In addition, 
there seems to be an interaction with other lipids, an inhibition of the cannabinoid receptor 
CB1, and of phospholipase A2 activity in mast cells.41
FTY720 has also been shown to increase brain-derived neurotrophic factor (BDNF) levels 
and ameliorates symptoms in methyl CpG binding protein 2 (MECP2)-null mice, a model of 
Rett syndrome.42 Whether this effect is S1P-mediated is not completely understood. BDNF 
is upregulated by seizures in animal models, and in brain specimens and blood serum from 
human pharmacoresistant epilepsy.43 The current understanding is that BDNF can 
significantly impact seizures, with either beneficial44 or detrimental effects being reported. 
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One recent study has shown both anti-inflammatory and antiepileptogenic effects of FTY720 
in a lithium-pilocarpine model of epilepsy in rats.45
Because FTY720 ameliorates symptoms of MECP2-null mice,42 we are performing a 
clinical study to assess safety and efficacy of oral FTY720 in children with Rett syndrome 
(FINGORETT). The study (phase I–II) has a focus on safety and was not designed for 
detecting therapeutic effects on seizures of FTY720 in those children. Nevertheless, 
information about seizure frequencies before, under, and after treatment are being collected, 
and EEG studies are recorded on a regular base within the study. The final results will be 
available in spring of 2017.
Future directions
FTY720 by its multiple modes of action on the immune system, the epigenetic machinery 
and BDNF signaling may be an interesting candidate as an anti-inflammatory and disease-
modifying drug for the treatment of refractory epilepsy. The good penetration across the 
BBB is another advantage of this drug. Approval and large clinical experience in patients 
with MS should facilitate and speed up the planning of a clinical trial.
Large Spectrum Anti-inflammatory Treatments: Friend or Foe?
(Federico Vigevano)
The evidence of neuroinflammation and immune mechanism involvement in the genesis of 
epilepsy is growing,1,25,46 thus opening the way to immune therapies for treating epilepsy. 
Immunotherapies are now routinely used in severe epilepsies with potential immune-
mediated pathogenesis, such as Rasmussen encephalitis, anti-NMDAR (N-methyl-D-
aspartate), anti-GAD (glutamic acid decarboxylase) or anti-VGKC (voltage gated potassium 
channel) complex encephalitis and fever-induced refractory epileptic encephalopathy in 
school-aged children.47,48 Beyond these clinical entities, drugs with anti-inflammatory and 
immunomodulatory actions are considered also in epileptic disorders lacking specific 
immunologic markers.49
Adrenocorticotropic hormone (ACTH) and corticosteroids (prednisone, prednisolone, and 
hydrocortisone) are widely used in some forms of epilepsies. ACTH and corticosteroids are 
mostly administered to treat patients with epileptic encephalopathy (EE), a group of severe 
clinical entities with heterogeneous clinical presentations and variable causes.50 EE includes 
prenatal causes like brain malformations, chromosomal or genetic abnormalities and 
neurocutaneous diseases, perinatal causes such as hypoxic ischemic injuries, and postnatal 
causes such as vascular or infectious insults.51 In EE, interictal epileptiform EEG 
abnormalities play a significant role in generating progressive deterioration in neurologic 
function.52 Thus the aim of treatment is not limited to seizure control; more often, the 
greatest challenge is to improve the child’s psychomotor development, a goal that requires 
suppression or reduction of interictal EEG discharges. With few exceptions, ACTH and 
corticosteroids are considered first-line agents in all cases of infantile spasms.53 Therapeutic 
efficacy has been also reported in other epileptic EE such as Lennox-Gastaut syndrome, 
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Landau-Kleffner syndrome, continuous spike and wave during sleep (CSWS), and other 
forms of epilepsy resistant to conventional AEDs.50
Little is known on the mechanism of the antiepileptic action of ACTH and corticosteroids, as 
well as on the pathogenesis of EE. However, various hypotheses have been put forward. At 
present the most accredited hypothesis is that ACTH and corticosteroids exert their actions 
through modulation of the hypothalamic-pituitary-adrenal axis. However, the possibility of 
direct effects on the immune system is also considered. In vitro, ACTH and corticosteroids 
stimulate the growth of neuroblasts, a property that might be relevant for the treatment of EE 
occurring in the first year of life. ACTH and corticosteroids may also modulate various 
neurotransmitter systems and voltage- or receptor-gated ion channels. In particular, ACTH 
downregulates serotonin 5HT2 receptors in the cerebral cortex, and modulates GABA and 
dopamine receptors, an effect that, in animal models, is age-dependent.54
In the last few years, increasing evidence has accumulated that certain forms of severe 
epilepsy could have an inflammatory and/or immunologic basis. Hence, the antiseizure 
effects of ACTH and corticosteroids, as well as immunoglobulins, may depend on their well-
known anti-inflammatory and immunosuppressant effects.55
ACTH and corticosteroids may cause significant adverse effects. In about two thirds of 
patients, a transient cerebral atrophy has been described, detectable by brain MRI. This 
finding may sometimes be a confounding factor in the diagnostic process. Transient 
dyskinesia with hyperkinetic movements involving face and limbs was observed during 
treatment with corticosteroids or ACTH. ACTH represents the first-line agent for the 
treatment of infantile spasms, except for spasms associated with tuberous sclerosis.56 
However, conclusive data supporting the long-term efficacy of ACTH are still lacking in the 
literature. There are also inadequate data on the optimal dosage and duration of therapy, 
although short duration and low dose are preferable. The issue of possible efficacy 
differences between natural and synthetic ACTH is also an object of debate.57
Future directions
Immunotherapy trials for the treatment of drug-resistant epilepsy represent a future 
therapeutic aim. This requires a better definition of how etiopathogenetic immune 
mechanisms are involved in the mechanisms of epileptogenesis.
The more precise concepts of how inflammation and the immune system may cause epilepsy 
and/or influence the course of disease will help to refine clinical trials involving the steroids 
as a class of anti-inflammatory drugs displaying broad effects on the immune system. These 
trials should also aim at identifying those steroid compounds that may be more effective and 
have a better adverse event profile.
Anti-Inflammatory Aspects of the Ketogenic Diet and PUFAs
(Stéphane Auvin, Jong M. Rho)
The ketogenic diet (KD) is a high-fat, low-carbohydrate diet characterized by ketonemia, 
relative hypoglycemia, and high fatty acids levels. The KD is an established treatment for 
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pharmacoresistant epilepsy, including some inflammation-induced epileptic 
encephalopathies such as febrile infection-related epilepsy syndrome (FIRES). Although the 
antiseizure mechanism(s) remain(s) unclear, new potential clinical applications for the KD 
are rapidly emerging, principally on the basis of its broad neuroprotective actions in various 
experimental models of neurologic disease, importantly those that significantly involve 
aberrant inflammatory responses.58
Although the KD has been investigated in multiple seizure and epilepsy models, variations 
on this metabolism-based treatment have also been administered in experimental models of 
pain, MS, Alzheimer’s and Parkinson’s diseases, neurotrauma, Autism Spectrum Disorder 
(ASD), and even malignant brain cancer (Table 1). Furthermore, there is now abundant 
evidence that the KD possesses anti-inflammatory properties, and specifically, this diet has 
been shown to decrease proinflammatory cytokine levels after an immune challenge.59 
Although the precise mechanisms underlying such effects in these models remain unclear, 
there are likely multiple, parallel, and synergistic processes and molecular targets, similar to 
what has been proposed for epilepsy.58 For example, polyunsaturated fatty acids (PUFAs), 
dietary lipids that contain more than one double bond, may play an important mechanistic 
role in KD action. Systemic PUFA levels rise in response to KD treatment, and have been 
reported to block epileptiform activity in models in vitro as well as in acutely provoked 
seizures in rodents. There are two groups of PUFAs: the omega-3 (n-3) and the omega-6 
(n-6) PUFAs. This nomenclature refers to the position of the double bond relative to the 
methyl terminal of the molecule.60 N-3 PUFAs can decrease the production of inflammatory 
eicosanoids, cytokines, and reactive oxygen species, and the expression of adhesion 
molecules. In addition,, n-3 PUFAs act both directly (by replacing arachidonic acid as an 
eicosanoid substrate and inhibiting arachidonic acid metabolism) and indirectly (by altering 
the expression of inflammatory genes through effects on transcription factor activation). In 
addition,, n-3 PUFAs, particularly eicosapentaenoic acid (EPA; 20:5n-3) and 
docosahexaenoic acid (DHA, 22:6n-3), also exert anti-inflammatory actions, primarily 
through their hydroxylated metabolites, which include resolvins and docosanoids.61 
Furthermore, PUFAs can bind to and activate peroxisome proliferator-activated receptors 
(PPARs), including both PPARα and PPARγ. It is notable that synthetic PPARs agonists 
have been shown to reduce experimentally induced inflammation. This effect is the result of 
the inhibition of pro-inflammatory pathways involving nuclear factor kappa B (NF-κB), 
signal transduction and transcription-1, and nuclear factor of activated T cells.62
Another KD-related mechanism involved in neuroinflammation is ketone-induced disruption 
of inflammasome assembly, and ketones such as β-hydroxybutyrate may modulate 
inflammation through actions on mitochondrial targets.63 Clearly, with growing evidence 
that the KD affords anti-inflammatory activity in a variety of animal models and human 
epileptic conditions (such as FIRES), the concept that inflammation as both a cause of and 
therapeutic target for epilepsy (and other neurologic conditions) is becoming more valid and 
worthy of further investigation.58,64
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Future directions
Preclinical studies should further characterize the mechanisms underlying the anti-
inflammatory effects of the KD and its substrates/mediators, not only for epilepsy but also 
for other neurologic disorders. One intriguing aspect is the potential inflammatory basis of 
comorbid conditions such as epilepsy and ASD. There is some preliminary clinical59 and 
growing experimental evidence65 that the KD is effective in mitigating core symptoms of 
ASD, and although the mechanisms underlying such behavioral benefits remain unclear, one 
intriguing possibility is diet-induced alterations in the gut microbiota, resulting in an anti-
microbial-like effect and comparable shifts in specific bacterial abundance seen in humans 
with autism.66 Clearly, the KD appears to render beneficial effects in both epilepsy and 
ASD. Further studies would provide a stronger scientific rationale for much-needed clinical 
trials for testing unique and complementary treatment approaches for affected patients.
Endocannabinoid System, CBIR/CB2Rs, and Inflammation
(Orrin Devinsky)
Δ9-THC modulates the endocannabinoid system, an endogenous signaling system with 
hydrophobic ligands N-arachidonoyl ethanolamide (anandamide, AEA)71 and 2-
arachidonoyl-glycerol (2-AG).72 These compounds are produced from postsynaptic 
membrane phospholipid precursors and released in an activity-dependent, “on-demand” 
manner. Hydrolysis of endocannabinoids produces arachidonic acid, a precursor for COX-2-
mediated production of inflammatory prostaglandins.73 AEA is degraded by the enzyme 
fatty acid amide hydrolase (FAAH) into arachidonic acid and ethanolamide,74,75 and 2-AG 
is catabolized by monoacylglycerol lipase (MAGL) and α/β-hydrolase domain containing 6 
(ABHD6)76 into arachidonic acid and glycerol.75–77 Inhibition of the degradative enzymes 
of AEA and 2-AG shunts lipid mediators away from proinflammatory prostaglandin 
mediators and toward anti-inflammatory endocannabinoids,68 thereby reducing neuropathic 
pain,78,79 Aβ-mediated inflammation, and oligodendrocyte excitotoxicity.81 In addition, 2-
AG directly inhibits COX-2 function, potentially via nuclear peroxisome proliferator–
activated receptor gamma (PPARγ) receptor.82
The primary targets for the endocannabinoids are the cannabinoid receptors type-1 (CB1R) 
and -2 (CB2R). CB1R is the primary CNS receptor, particularly in the hippocampal mossy 
cell-granule cell synapses, and to a lesser extent, on microglia, astrocytes, and 
oligodendrocytes.74 Although implicated primarily in peripheral signaling, CB2Rs are also 
expressed in the brain,83 mediating neuronal excitability84 and inflammation in microglia.85 
Kainic acid-induced status epilepticus86 and lipopolysaccharide (LPS)-induced 
inflammation87 upregulate CB1R expression, either as a direct consequence of 
inflammation-induced sequelae or as a potential compensatory mechanism to limit 
prolonged hyperexcitability. Supporting a potential anti-inflammatory role of CB1R/CB2Rs, 
CB2R agonism decreases microglial activation, edema, excitotoxicity, oxidative stress, and 
cell death associated with stroke,88 germinal matrix hemorrhage,89 and traumatic brain 
injury. Furthermore, activation of CB1Rs91 and CB2Rs92 via synthetic agonists reduced 
inflammatory nociception in several animal models.
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Δ9-Tetrahydrocannabinol (Δ9-THC) and inflammation
Both cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) produce net anti-
inflammatory effects, although through different target receptor mechanisms (Table 2). Δ9-
THC acts primarily as a partial agonist at CB1Rs and CB2Rs on microglia, the primary CNS 
immune cells. Δ9-THC reduces LPS-induced inflammation in vitro and in vivo by limiting 
release of the pro-inflammatory cytokines IL-1β, IL-6, IL-17, tumor necrosis factor α 
(TNFα), and interferon β (IFNβ), and elevating anti-inflammatory cytokines such as 
IL-10.88–94 These effects may be age-specific, however, as treating adolescent mice Δ9-THC 
exerts opposite effects when assayed later in life, increasing pro-inflammatory and 
decreasing anti-inflammatory cytokine release.95 In other studies, Δ9-THC limits oxidative 
stress in LPS-triggered inflammation,98 reduces nitrite formation following intravitreal 
NMDA injection,99 and decreases glutamate neurotoxicity and oxidative stress.100 Anti-
oxidative effects of Δ9-THC may be independent from, or only partially mediated by, 
CB1Rs/CB2Rs.100,101 Other proposed anti-inflammatory targets for Δ9-THC (or related 
compound Δ9-tetrahydrocannabivarin, Δ9-THCV) include transient activation and 
desensitization of TRP (transient receptor potential) channels TRPA1, TRPV1–4,102–104 and 
antagonism of TRPM8,103 which may regulate postinflammatory Ca2+ influx. Similar to 
endocannabinoids, Δ9-THC may reduce COX-2 activation via PPARγ,105 although a Δ9-
THC-mediated, CB1R-dependent increase in COX-2 and PGE2106 may be dose dependent. 
Collectively, Δ9-THC primarily exerts anti-inflammatory properties in animal models of 
inflammation (in vivo) including cerebral artery occlusion–induced ischemia,107,108 acute 
palmar inflammation,109 5XFAD APP transgenic (Alzheimer’s disease model) mice,106 and 
the myelin oligodendrocyte glycoprotein (MOG)35-55-induced experimental autoimmune 
encephalomyelitis model of MS.101
Cannabidiol (CBD) and inflammation
CBD has very low affinity at CBRs,110,111 but acts as an agonist at TRP channels (TRPV1, 
TRPV2, and TRPA1),103,104,110,112 5HT1α receptors,113 and glycine receptors.114 CBD is 
an antagonist at TRPM8 channels,102 T-type voltage-gated calcium channels,115 and the G 
protein-coupled receptor GPR55.116 CBD may have unique effects on inflammation through 
dynamic regulation of intracellular calcium stores via multiple, activity-dependent 
pathways.117 CBD induces a bidirectional change in intracellular calcium levels that 
depends on cellular excitability: slightly increasing intracellular [Ca2+] under normal 
physiologic Ca2+ conditions and reducing intracellular [Ca2+] under high-excitability 
conditions. These changes may be mediated by the mitochondrial Na+/Ca2+ exchanger.117 
CBD also produces biphasic changes in intracellular calcium levels via antagonism of the 
mitochondrial VDAC1 channel.118 Furthermore, CBD is an agonist at PPARγ119 and 
competitive antagonist at the equilibrative nucleotide transporter (ENT-1), reducing 
adenosine uptake at baseline120 and during LPS-induced inflammation in vitro121 and in 
vivo.120
CBD exerts dynamic changes in intracellular signaling to reduce oxidative stress, as assayed 
via genome-wide microarray studies. At baseline, CBD treatment in cell cultures targets 
pathways implicated in oxidative stress and glutathione depletion (e.g., GCN2, PKR, and 
eIF2a) and nuclear oxidative stress response (e.g. Nrf2).122,123 Upon LPS stimulation, CBD 
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triggers Nrf2 activation, inhibits NFκB and AP-1, and activates MAPK, JAK/STAT, and cell 
cycle regulatory pathways, producing net anti-inflammatory effects and 
immunosuppression.94,124 CBD regulates oxidative stress post hypoxic-ischemia107,113,125 
and oxygen-glucose deprivation, in part by reducing LDH efflux, caspase-9 activation, and 
iNOS expression.126 Similar to Δ9-THC, CBD reduces pro-inflammatory cytokines and 
IFNβ/γ and increases anti-inflammatory cytokines such as IL-4 and IL-10 via a CB1R/
CB2R mechanism, potentially through adenosine or PPARγ 
signaling.94,101,113,120,122,126,127 This mechanism also limits Th17 differentiation and 
function, and reduces leukocyte transmigration, partly by downregulating VCAM-1, CCL2, 
and CCL5, in animal models of MS.124,128 In addition, CBD increases cell survival and 
reduces oxidative stress in in vitro and in vivo models of Aβ (1–42)-induced 
inflammation.126–129
Cannabinoids and neuroprotection from seizures
The anti-inflammatory effects of the endocannabinoid system, Δ9-THC, and CBD may help 
to explain the neuroprotective effects of cannabinoids in animal models of seizures. In 
chronic (e.g., pilocarpine-induced) seizure models, synthetic CB1R agonism130 or 
CBD131,132 administered during the chronic phase reduces neuronal damage and oxidative 
stress/autophagy. In acute (e.g., kainic acid) preclinical studies, CB1R activity133 or elevated 
endocannabinoid signaling134,135 provides neuroprotective effects postseizure.
Future directions
CBDs are potentially promising anti-inflammatory drugs. Yet the specific nature, extent, and 
specificity of their immunomodulatory and immunosuppressive effects remain to be 
determined. The role of cannabinoids as therapeutic agents against inflammatory and 
autoimmune disorders, including selected epilepsy syndromes, deserves further study.
Anti-Inflammatory Mechanisms of Vagus Nerve Stimulation
(Peder S. Olofsson)
Accumulating evidence suggests that inflammation and immune system activation may play 
a role in epileptogenesis and lowering seizure threshold, and that anti-inflammatory 
treatments improve the disease outcomes.136–139 Discoveries in bioelectronic medicine, 
which is the convergence of neuroscience, engineering, computing, and clinical medicine, 
have revealed that nerve stimulation has the capacity to regulate inflammation, cytokine 
release, and other immune system functions.140–143 It is becoming increasingly clear that the 
immune system no longer can be regarded as fully autonomous, because it is regulated by 
neural reflex circuits.
The best characterized neural reflex that regulates cytokine release in inflammation is the so 
called “inflammatory reflex,” in which the vagus nerve plays a key role. Electrical vagus 
nerve stimulation has been used for treatment of drug-resistant epilepsy since the 1990s144 
and for refractory depression for more than a decade.145 Vagus nerve stimulators have been 
implanted in tens of thousands of patients, and few significant adverse effects have been 
reported.146–148 The neurophysiologic and molecular mechanisms that underlie the 
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therapeutic effect of vagus nerve stimulation in epilepsy and depression are, however, not 
well understood.
Electrical stimulation of the cervical vagus nerve reduces inflammation in a number of 
experimental inflammatory diseases, ranging from sepsis, over ischemia-reperfusion injury, 
to experimental arthritis.141,149 The bridging of neuroscience and immunology has revealed 
specific molecular targets of neural reflex signals in inflammation.150 Neurophysiologic and 
molecular mapping of the efferent arc of the inflammatory reflex has demonstrated that 
electrical activation of the left cervical vagus nerve triggers signals in the efferent vagus 
nerve that reach the celiac ganglion where the splenic nerve arises.151,152 The splenic nerve 
is required for relaying the signals to the spleen, where choline acetyl-transferase (ChAT)+ T 
cells, “CD4 TChAT,” which appear in close apposition of splenic nerve endings, release 
acetylcholine in response to norepinephrine.153 Acetylcholine subsequently activates α7 
nicotinic acetylcholine receptors (α7nAChRs) on innate immune cells, including splenic 
macrophages, which significantly reduce release of proinflammatory cytokines such as 
TNF-α in experimental systemic inflammation.144,154 Vagus nerve stimulation also reduces 
infiltration of leukocytes in local inflammation,155 inhibits macrophage activation,156 and 
promotes a reparative phenotype of macrophages at sites of injury.157
Intriguingly, the discovery that CD4 TChAT relay neural signals afford a mechanism for 
providing cholinergic signals to tissues devoid of cholinergic innervation. As an example, 
most blood vessels are devoid of cholinergic innervation, but vascular endothelial cells 
express cholinergic receptors. Activation of endothelial cholinergic receptors promotes 
release of nitric oxide that reduces blood pressure by relaxing vascular smooth muscle 
cells.158 CD4 TChAT are found in murine blood, and mice deficient in CD4 TChAT show 
significantly increased blood pressure and their cardiovascular physiology is consistent with 
an increased systemic vascular resistance.159 These observations indicate that CD4 TChAT 
regulates blood pressure by providing a cholinergic signal to vascular endothelial cells, and 
it is conceivable that neurotransmitter-releasing immune cells may interact with nerves and 
organs to regulate physiology in additional ways not yet discovered.
The new insights on reflex control of inflammation and, in particular, on the inflammatory 
reflex, have spawned clinical trials for treatment of chronic human inflammatory diseases 
using an implantable vagus nerve stimulator developed originally for treatment of 
epilepsy.142 The first reports on its effects in rheumatoid arthritis and inflammatory bowel 
disease are encouraging, with improved clinical scores and attenuated release of pro-
inflammatory cytokines.160,161 The study population sizes were, however, limited, and 
results from larger clinical trials that may improve our understanding of the usefulness of 
vagus nerve stimulation in treatment inflammatory diseases are eagerly awaited.
In light of the accumulating evidence that inflammation plays a role in epileptogenesis and 
seizure threshold reduction, and the anti-inflammatory effects of vagus nerve stimulation, it 
is tempting to speculate that one mechanism that underlies the therapeutic effect of vagus 
nerve stimulation in epilepsy involves attenuation of inflammation. In a recent study, Varvel 
et al. observed that infiltrating monocytes exacerbate neuronal damage and increase 
morbidity after status epilepticus.28 Spleen can deploy a significant portion of the monocytes 
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recruited to sites of inflammation.158,162 Vagus nerve stimulation reduces cytokine release 
from innate immune cells in spleen and may shift macrophage phenotype from pro-
inflammatory to reparative.143 It would be interesting to investigate whether vagus nerve 
stimulation can reduce epileptogenesis by reducing local neuroinflammation perhaps by 
local direct effects in the CNS and/or by reducing the pro-inflammatory activity of 
infiltrating immune cells.
Future directions
Despite the convincing physiologic effects of vagus nerve stimulation in experimental 
models of inflammatory diseases and the comprehensive understanding of some of the 
molecular pathways in neural regulation of inflammation, the mechanistic basis for the 
therapeutic effect of vagus nerve stimulation on epilepsy is currently unclear. Further studies 
of the neurophysiology and molecular mechanisms that underlie the neural control of 
immune cell activity both in the periphery and in the CNS are warranted to improve our 
understanding of the pathogenesis of neuroinflammation and epilepsy.
Conclusions and Future Directions
During the past years, it has been recognized that anti-inflammatory mechanisms play an 
important role in the antiseizure effect of established therapies for epilepsy, like the KD and 
vagus nerve stimulation. In addition, a variety of drugs, like CBDs, are under scrutiny for 
their use as antiseizure drugs, which work through a substantial anti-inflammatory 
mechanism and which also may have a potential antiepileptogenic effect. When testing these 
two issues, future trials need to adopt more sophisticated designs with enrollment of 
“enriched” patients. Treatment of therapy-resistant patients with CBDs or specific anti-
inflammatory drugs already approved for other indications, like fingolimod or anakinra, 
needs to adhere to such a protocol. Prevention of epilepsy after stroke or traumatic brain 
injury may be another opportune clinical situation for conducting antiepileptogenesis trials. 
Patterns of adverse events of anti-inflammatory drugs should be closely monitored because 
they are likely to be different from those observed in classic AEDs. Fostering a network of 
experimental and clinical research collaborations from academia, industry, and funding 
institutions is germane for further progress in the translation of preclinical research results 
into clinical studies for the sake of patients at risk of developing the disease or with difficult-
to-treat epilepsy.
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Key Points
• Specific anti-inflammatory treatments have been effective at suppressing 
experimental chronic seizures and interfering with epileptogenesis
• Some of these drugs have already been evaluated in early phase clinical trials 
in pharmacoresistant epilepsies
• Nonpharmaceutical therapies for refractory epilepsy like the ketogenic diet or 
vagus nerve stimulation influence the immune system
• Novel clinical trial design trials should contain an end-point to demonstrate 
disease modification
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Table 1
Examples of utilization of KD as an anti-inflammatory treatment for various pathologic models
References Type of diet Species Model Anti-inflammatory effect of KD
67 6.6:1 KD
3 weeks before Exp.
Rats Subcutaneous injection of 
complete Freund’s adjuvant into 
one hind paw
Decrease both swelling and plasma 
extravasation
68 Made by the lab
2 weeks before Exp.
C57BL/6J Mice MPTP model Decrease of activated microglia
(Iba 1 staining)
Decrease of IL1β, IL-6, TNFα (ELISA of 
SN)
69 6.3:1 KD (Bio-Serv 
F3666 diet)
7 days before Exp.
C57BL/6 mice Experimental autoimmune 
encephalomyelitis
S.C. myelin oligodendrocyte 
glycoprotein (MOG)35–55 
peptide + complete Freund’s 
adjuvant (CFA)
I.V. 20 ng of pertussis toxin
2-2.5-fold reduction in CNS-derived CD4+ 
cells and CD11b+ CD45+ cells (macrophage 
and microglia tendency toward increased 
CD4+ CD25+ Foxp3+ Treg cells
Lymph node & CNS reduction in cytokines 
(IL-1β, IL-6, TNF-α, IL-12, IL-17) and 
chemokines (IFN-γ, MCP-1, MIP-1a, 
MIP-1b)
70 6.3:1 KD (Bio-Serv 
F3666 diet)
4 weeks before Exp.
C57BL/6 mice Liver and white adipose tissue 
(WAT)
Liver: Increase of expression of Tnfα, Il-6, 
Emr1, Cd68, Itgam, Nlrp3
WAT: Decrease of expression of Tnfα, Il-6, 
Emrl, Cd68, Itgam, Nlrp3
58 3:1 KD (Ketocal)
2 weeks before Exp.
Wistar rats Fever model
50 μg/kg of LPS (Escherichia 
coli 055:B5)
Modulate raise of body temperature
Blood: Reduce IL-1β, TNF-α
Brain: Reduce IL-1β mRNA
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Table 2
Potential anti-inflammatory mechanism of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD)
Anti-inflammatory mechanism References
Δ9-THC (1) CB1R/CB2R partial agonist 137
(2) ↓pro-inflammatorycytokines (IL-1β, IL-6, IL-17, TNFα, IFNβ) ↑ anti-inflammatorycytokine (IL-10) 93–97
(3) TRP channels agonist (TRPV1-4, TRPA1), TRPM8 antagonist 102–104
(4) ↓(or↑) COX-2 activation via PPARγ, dose-dependent 105, 106
CBD (1) Regulation of intracellular Ca2+ via mitochondrial Na+/Ca2+ exchanger, or VDAC channel 117, 118
(2) Inhibition of ENT-1 transporter, ↑ adenosine at A2A receptor 120, 121
(3) ↓pro-inflammatory cytokines (IL-Iβ, IL-3, IL-6, IL-12, IL-17, TNFα, IFNβ/γ) ↑ anti-inflammatory 94, 101, 113, 120, 121, 125, 127
cytokines (IL-4, IL-10) 102–104
(4) TRP channels agonist (TRPV1–4, TRPA1), TRPM8 antagonist 116
(5) G-protein-coupled-receptor GPR55 antagonist 105
(6) ↓ COX-2activation via PPARγ 124, 128
(7) ↓ activation of microglial VCAM-I, CCL2, CCL5 transmigration of leukocytes, (mediated in part by 
adenosine A2A receptors)
94, 122–124, 126
(8) ↓ oxidative stress, lipid peroxidation, caspase 3 activation, ROS (iNOS, NO), nuclear stress response 
(Nrf2→ ↓NFκB, ↑STAT3)
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